Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial

Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” was added, and the site revision label advanced from v3.7.1 to v3.7.2. The study-record area still displays a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-10-21T13:46:05.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-07T14:27:23.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, blocking access to the study record. Previous study-related terms and content appear removed or hidden due to the access restriction.
    Difference
    22%
    Check dated 2026-09-23T19:56:09.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Revision: v3.7.0 has been added, replacing the previous Revision: v3.6.6. The page now reflects the newer revision version.
    Difference
    0.0%
    Check dated 2026-09-16T21:53:28.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page's revision indicator was updated from v3.6.5 to v3.6.6, signaling a maintenance update to the page. The study details and content remain unchanged.
    Difference
    0.0%
    Check dated 2026-09-02T18:15:30.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    The study record shows administrative updates with a new revision number (v3.6.5) and recent dates, while older timestamps were removed, indicating metadata maintenance rather than substantive changes to the study details.
    Difference
    0.3%
    Check dated 2026-08-12T09:13:56.000Z thumbnail image

Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.